Patents by Inventor Beatrice Tien-Yi Wang

Beatrice Tien-Yi Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MULTIMERIC GITR BINDING MOLECULES AND USES THEREOF
    Publication number: 20220177595
    Abstract: This disclosure provides dimeric, pentameric, and hexameric GITR agonist binding molecules and methods of using such binding molecules to induce anti-tumor immunity.
    Type: Application
    Filed: February 24, 2022
    Publication date: June 9, 2022
    Inventors: Beatrice Tien-Yi WANG, Bruce Alan KEYT, Ramesh BALIGA
  • MULTIMERIC OX40 BINDING MOLECULES AND USES THEREOF
    Publication number: 20220169751
    Abstract: This disclosure provides dimeric, pentameric, and hexameric OX40 agonist binding molecules and methods of using such binding molecules to induce anti-tumor immunity.
    Type: Application
    Filed: February 17, 2022
    Publication date: June 2, 2022
    Inventors: Beatrice Tien-Yi WANG, Dalya Rivka ROSNER, Ramesh BALIGA, Bruce KEYT
  • MULTIMERIC CD40 BINDING MOLECULES AND USES THEREOF
    Publication number: 20220106399
    Abstract: This disclosure provides dimeric, pentameric, and hexameric CD40 agonist binding molecules and methods of using such binding molecules to induce anti-tumor immunity.
    Type: Application
    Filed: December 17, 2021
    Publication date: April 7, 2022
    Inventors: Ramesh BALIGA, Beatrice Tien-Yi WANG, Dalya Rivka ROSNER, Bruce KEYT
  • MULTIMERIC CD137/4-1BB BINDING MOLECULES AND USES THEREOF
    Publication number: 20210388098
    Abstract: This disclosure provides dimeric, pentameric, and hexameric CD137/4-1BB agonist binding molecules and methods of using such binding molecules to induce anti-tumor immunity.
    Type: Application
    Filed: August 17, 2021
    Publication date: December 16, 2021
    Inventors: Bruce KEYT, Ramesh BALIGA, Beatrice Tien-Yi WANG
  • CD20 BINDING MOLECULES AND USES THEREOF
    Publication number: 20210032357
    Abstract: This disclosure provides pentameric and hexameric CD20 binding molecules and methods of using such molecules to direct complement-mediated, T-cell-mediated, or both complement-mediated and T-cell-mediated killing of CD20-expressing cells.
    Type: Application
    Filed: July 24, 2020
    Publication date: February 4, 2021
    Inventors: Bruce Alan Keyt, Omar Duramad, Beatrice Tien-Yi Wang, Ramesh Baliga, Fen Zhang
  • USE OF A MULTIMERIC ANTI-DR5 BINDING MOLECULE IN COMBINATION WITH A CHEMOTHERAPEUTIC AGENT FOR TREATING CANCER
    Publication number: 20200392239
    Abstract: This disclosure provides therapeutic methods for treating cancer including combination therapy with a multimeric anti-DR5 antibody and a chemotherapeutic agent, e.g., a type I topoisomerase inhibitor, a nucleoside analog, or a pro-apoptotic agent, e.g., a BCL-2 inhibitor.
    Type: Application
    Filed: February 25, 2019
    Publication date: December 17, 2020
    Inventors: Beatrice Tien-Yi WANG, Bruce Alan KEYT
  • Multimeric bispecific binding molecules specific for CD20 and CD3
    Patent number: 10787520
    Abstract: This disclosure provides pentameric and hexameric CD20 binding molecules and methods of using such molecules to direct complement-mediated, T-cell-mediated, or both complement-mediated and T-cell-mediated killing of CD20-expressing cells.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: September 29, 2020
    Assignee: IGM Biosciences, Inc.
    Inventors: Bruce Alan Keyt, Omar Duramad, Beatrice Tien-Yi Wang, Ramesh Baliga, Fen Zhang
  • Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof
    Patent number: 10689449
    Abstract: This disclosure provides dimeric, pentameric, and hexameric Tumor Necrosis Factor (TNF) superfamily receptor protein binding molecules and methods of using such binding molecules to direct apoptosis-mediated killing of TNF receptor-expressing cells.
    Type: Grant
    Filed: January 20, 2016
    Date of Patent: June 23, 2020
    Assignee: IGM Biosciences, Inc.
    Inventors: Beatrice Tien-Yi Wang, Max A. Schwarzer, Bruce Alan Keyt, Ramesh Baliga
  • MULTIMERIC CD40 BINDING MOLECULES AND USES THEREOF
    Publication number: 20190338041
    Abstract: This disclosure provides dimeric, pentameric, and hexameric CD40 agonist binding molecules and methods of using such binding molecules to induce anti-tumor immunity.
    Type: Application
    Filed: July 19, 2017
    Publication date: November 7, 2019
    Inventors: Ramesh BALIGA, Beatrice Tien-Yi Wang, Dalya Rivka ROSNER, Bruce Alan Keyt
  • MULTIMERIC CD137/4-1BB BINDING MOLECULES AND USES THEREOF
    Publication number: 20190338040
    Abstract: This disclosure provides dimeric, pentameric, and hexameric CD137/4-1BB agonist binding molecules and methods of using such binding molecules to induce anti-tumor immunity.
    Type: Application
    Filed: July 19, 2017
    Publication date: November 7, 2019
    Inventors: Bruce Alan Keyt, Ramesh BALIGA, Beatrice Tien-Yi Wang
  • MULTIMERIC OX40 BINDING MOLECULES AND USES THEREOF
    Publication number: 20190330374
    Abstract: This disclosure provides dimeric, pentameric, and hexameric OX40 agonist binding molecules and methods of using such binding molecules to induce anti-tumor immunity.
    Type: Application
    Filed: July 20, 2017
    Publication date: October 31, 2019
    Inventors: Beatrice Tien-Yi WANG, Dalya Rivka Rosner, Ramesh BALIGA, Bruce Alan Keyt
  • MULTIMERIC GITR BINDING MOLECULES AND USES THEREOF
    Publication number: 20190330360
    Abstract: This disclosure provides dimeric, pentameric, and hexameric GITR agonist binding molecules and methods of using such binding molecules to induce anti-tumor immunity.
    Type: Application
    Filed: July 20, 2017
    Publication date: October 31, 2019
    Inventors: Beatrice Tien-Yi WANG, Bruce Alan Keyt, Ramesh BALIGA
  • CD20 BINDING MOLECULES AND USES THEREOF
    Publication number: 20190100597
    Abstract: This disclosure provides pentameric and hexameric CD20 binding molecules and methods of using such molecules to direct complement-mediated, T-cell-mediated, or both complement-mediated and T-cell-mediated killing of CD20-expressing cells.
    Type: Application
    Filed: March 4, 2015
    Publication date: April 4, 2019
    Applicant: IGM Biosciences, Inc.
    Inventors: Bruce Keyt, Omar Duramad, Beatrice Tien-Yi Wang, Ramesh Baliga, Fen Zhang
  • Tumor necrosis factor (TNF) superfamily receptor IgM antibodies and uses thereof
    Patent number: 9938347
    Abstract: This disclosure provides dimeric, pentameric, and hexameric Tumor Necrosis Factor (TNF) superfamily receptor protein binding molecules and methods of using such binding molecules to direct apoptosis-mediated killing of TNF receptor-expressing cells.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: April 10, 2018
    Assignee: IGM BIOSCIENCES A/S
    Inventors: Beatrice Tien-Yi Wang, Max Allen Schwarzer, Bruce Alan Keyt, Ramesh Baliga
  • TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY RECEPTOR BINDING MOLECULES AND USES THEREOF
    Publication number: 20180009897
    Abstract: This disclosure provides dimeric, pentameric, and hexameric Tumor Necrosis Factor (TNF) superfamily receptor protein binding molecules and methods of using such binding molecules to direct apoptosis-mediated killing of TNF receptor-expressing cells.
    Type: Application
    Filed: January 20, 2016
    Publication date: January 11, 2018
    Inventors: Beatrice Tien-Yi Wang, Max A. Schwarzer, Bruce Keyt, Ramesh Baliga
  • TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY RECEPTOR BINDING MOLECULES AND USES THEREOF
    Publication number: 20170320955
    Abstract: This disclosure provides dimeric, pentameric, and hexameric Tumor Necrosis Factor (TNF) superfamily receptor protein binding molecules and methods of using such binding molecules to direct apoptosis-mediated killing of TNF receptor-expressing cells.
    Type: Application
    Filed: June 30, 2017
    Publication date: November 9, 2017
    Inventors: Beatrice Tien-Yi Wang, Max Allen Schwarzer, Bruce Alan Keyt, Ramesh Baliga